The FDA has approved the new drug application of a ready-to-dilute formulation of a treatment for breast and ovary adenocarcinoma.
Cancer cells, malignant cells, generative ai illustration: © Dr_microbe - stock.adobe.com
The FDA has accepted a new drug application (NDA) of SH-105, a ready-to-dilute formula of an existing treatment for adenocarcinoma of the breast or ovary. The PDUFA target action date is June 24, 2024.1
“This innovative drug will offer hospital pharmacists and patients access to a differentiated, ready to administer, injectable product with unique characteristics that’s expected to facilitate rapid adoption once approved,” said Orlaith Ryan, chief technical officer and co-founder of Shorla Oncology, in a press release.
The original agent SH-105 improved upon was approved in the 1950s and has not been updated since, according to Ryan.2 The ready-to-dilute formulation simplifies the drug reconstitution process, which can improve efficiency and reduce preparation risks for clinicians, therefore increasing satisfaction and safety for patients.
Shorla Oncology has several other agents in its development pipeline. SH-110 is an oral treatment for glioma, and the company has had a pre-investigational new drug application meeting with the FDA. SH-201 is an oral treatment for chronic myeloid leukemia, acute lymphoblastic leukemia (ALL), myelodysplastic syndrome, and gastrointestinal tumors. The company plans to submit an NDA to the FDA for SH-201 in Q1 of this year. The company also manufactuers Jylamvo, the only approved, oral methotrexate solution for adults, and nelarabine, an injection for the treatment of T-cell ALL and T-cell lymphoblastic lymphoma.3
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More